Ampio Pharmaceuticals Inc. (AMEX:AMPE) went down by -3.38% from its latest closing price compared to the recent 1-year high of $2.98. The company’s stock price has collected -6.54% of loss in the last five trading sessions. Press Release reported on 01/04/21 that Ampio Provides Update on Clinical Trials for Ampion(TM) Treatment of COVID-19 Patients
Is It Worth Investing in Ampio Pharmaceuticals Inc. (AMEX :AMPE) Right Now?
Plus, the 36-month beta value for AMPE is at 1.76. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Ampio Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $4.00. AMPE currently public float of 170.96M and currently shorts hold a 11.02% ratio of that float. Today, the average trading volume of AMPE was 5.48M shares.
AMPE’s Market Performance
AMPE stocks went down by -6.54% for the week, with a monthly jump of 18.18% and a quarterly performance of 69.25%, while its annual performance rate touched 116.73%. The volatility ratio for the week stands at 7.83% while the volatility levels for the past 30 days are set at 24.47% for Ampio Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -17.17% for AMPE stocks with a simple moving average of 70.39% for the last 200 days.
Analysts’ Opinion of AMPE
Many brokerage firms have already submitted their reports for AMPE stocks, with ROTH Capital repeating the rating for AMPE by listing it as a “Buy.” The predicted price for AMPE in the upcoming period, according to ROTH Capital is $4 based on the research report published on December 19th of the previous year 2019.
Aegis Capital, on the other hand, stated in their research note that they expect to see AMPE reach a price target of $16, previously predicting the price at $15. The rating they have provided for AMPE stocks is “Buy” according to the report published on March 17th, 2014.
Aegis Capital gave a rating of “Buy” to AMPE, setting the target price at $11 in the report published on September 25th of the previous year.
AMPE Trading at 15.49% from the 50-Day Moving Average
After a stumble in the market that brought AMPE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.01% of loss for the given period.
Volatility was left at 24.47%, however, over the last 30 days, the volatility rate increased by 7.83%, as shares sank -4.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +72.29% upper at present.
During the last 5 trading sessions, AMPE fell by -6.54%, which changed the moving average for the period of 200-days by +231.02% in comparison to the 20-day moving average, which settled at $1.7230. In addition, Ampio Pharmaceuticals Inc. saw -10.06% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AMPE
The total capital return value is set at -282.57, while invested capital returns managed to touch -211.50. Equity return is now at value -192.90, with -97.90 for asset returns.
Based on Ampio Pharmaceuticals Inc. (AMPE), the company’s capital structure generated 22.80 points at debt to equity in total, while total debt to capital is 18.57. Total debt to assets is 10.49, with long-term debt to equity ratio resting at 18.78. Finally, the long-term debt to capital ratio is 15.29.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.